A Study of Soticlestat and Rifampin in Healthy Adults

Sponsor
Takeda (Industry)
Overall Status
Recruiting
CT.gov ID
NCT05098041
Collaborator
(none)
14
Enrollment
1
Location
1
Arm
1.3
Anticipated Duration (Months)
10.9
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The main aim of this study is to check how rifampin affects the way soticlestat is processed by the body.

Participants will be required to stay at the study clinic for 18 consecutive days. On the first full day and 15th day, participants will take a single dose of soticlestat. Rifampin will be taken each day starting on the 5th day for 13 consecutive days.

Clinic staff will follow up with each participant about 15 days after the last soticlestat dose to check for any side effects.

Condition or DiseaseIntervention/TreatmentPhase
Phase 1

Detailed Description

The drug being tested in this study is called soticlestat (TAK-935). The study will evaluate the safety and tolerability of soticlestat when co-administered with rifampin in healthy participants.

The study will enroll 14 participants. The participants will be assigned to treatment group to receive following therapies:

• Soticlestat 300 milligram (mg) + Rifampin 600 mg

The study will have two periods: Period 1 and Period 2. In Period 1, participants will receive soticlestat in fasted condition while in Period 2 participants will receive soticlestat along with rifampin. The data will be collected and stored in electronic case report form (eCRF).

This single-center trial will be conducted in the United Kingdom. The overall study duration of the study will be approximately 58 days including 28 days screening and follow up duration. There will be a follow up contact required for all participants approximately 15 days after the last dose of soticlestat.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
14 participants
Allocation:
N/A
Intervention Model:
Sequential Assignment
Masking:
None (Open Label)
Primary Purpose:
Basic Science
Official Title:
A Phase 1 Open-Label Study to Evaluate the Drug-Drug Interaction of Rifampin as a Strong CYP3A Inducer on Soticlestat Pharmacokinetics in Healthy Adult Participants
Actual Study Start Date :
Nov 22, 2021
Anticipated Primary Completion Date :
Dec 20, 2021
Anticipated Study Completion Date :
Dec 31, 2021

Arms and Interventions

ArmIntervention/Treatment
Experimental: Soticlestat 300 mg + Rifampin 600 mg

Soticlestat 3*100 mg tablets, orally, administered once on Day 1 in fasted state in Period 1, followed by a washout period of 4 days, further followed by Rifampin 600 mg, administered as 2*300mg capsules, orally, once daily for 13 consecutive days, from Day 1 to Day 13 in fasted state in Period 2. Soticlestat 3*100 mg tablets, will be administered orally along with rifampin 600 mg (2*300mg) capsules, orally in the morning of Day 11 in Period 2.

Drug: Soticlestat
Soticlestat tablets.
Other Names:
  • TAK-935
  • Drug: Rifampin
    Rifampin capsules.

    Outcome Measures

    Primary Outcome Measures

    1. Cmax: Maximum Observed Plasma Concentration for Soticlestat [Period 1: Day 1 pre-dose and at multiple time points (up to 96 hours) post-dose; Period 2: Day 11 pre-dose and multiple time points (up to 72 hours) post-dose]

    2. AUC∞: Area Under the Plasma Concentration-time Curve from Time 0 to Infinity for Soticlestat [Period 1: Day 1 pre-dose and at multiple time points (up to 96 hours) post-dose; Period 2: Day 11 pre-dose and multiple time points (up to 72 hours) post-dose]

    3. AUClast: Area Under the Plasma Concentration-time Curve from Time 0 to the Time of the Last Quantifiable Concentration for Soticlestat [Period 1: Day 1 pre-dose and at multiple time points (up to 96 hours) post-dose; Period 2: Day 11 pre-dose and multiple time points (up to 72 hours) post-dose]

    4. Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for Soticlestat [Period 1: Day 1 pre-dose and at multiple time points (up to 96 hours) post-dose; Period 2: Day 11 pre-dose and multiple time points (up to 72 hours) post-dose]

    Secondary Outcome Measures

    1. Number of Participants With at Least One Treatment-emergent Adverse Event (TEAE) [Baseline up to Day 58]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 55 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion criteria:
    1. Healthy, adult, male or female of non-childbearing potential, 18-55 years of age, inclusive, at screening.

    2. Has body mass index (BMI) greater than or equal to (>=) 18.0 and less than or equal to (<=) 32.0 kilogram per square meter (kg/m^2) at screening.

    3. Continuous non-smoker who has not used nicotine-containing products for at least 90 days prior to the first dosing.

    4. Able to swallow multiple tablets/capsules.

    Exclusion criteria:
    1. Has history of any illness that, in the opinion of the Investigator or designee, might confound the results of the study or poses an additional risk to the participant by their participation in the study.

    2. Any positive responses on the C-SSRS that in the clinical judgment of the Investigator has a risk of suicide or has made a suicide attempt in the previous 12 months prior to the first dosing.

    3. Unable to refrain from or anticipates the use of:

    • Any drug, including prescription and non-prescription medications, herbal remedies, or vitamin supplements within 14 days prior to the first dosing. Thyroid hormone replacement medication may be permitted if the participant has been on the same stable dose for the immediate 3 months prior to first dosing.

    • Any drugs known to be significant inducers of cytochrome (CYP)3A, CYP2C19, UGT1A9 or UGT2B4 enzymes, and/or P-glycoprotein (P-gp), including St. John's Wort, within 28 days prior to the first dosing.

    Appropriate sources (example, Flockhart TableTM) will be consulted to confirm lack of pharmacokinetic (PK)/pharmacodynamics interaction with study drug.

    1. History of alcohol consumption exceeding 2 standard drinks per day on average (1 glass is approximately equivalent to the following: beer 354 milliliter [mL]/12 ounce [oz], wine [118 mL/4 oz], or distilled spirits [29.5 mL/1 oz] per day).

    2. Consumes excessive amounts, defined as greater than 4 servings (1 serving is approximately equivalent to 120 mg of caffeine), of coffee, tea, cola, energy drinks, or other caffeinated beverages per day.

    3. Has been on a diet incompatible with the on-study diet, in the opinion of the Investigator or designee, within the 30 days prior to the first dosing and throughout the study.

    4. Donation of blood or significant blood loss within 56 days prior to the first dosing.

    5. Plasma donation within 7 days prior to the first dosing.

    6. Participation in another clinical study within 30 days or 5 half-lives prior to the first dosing. The 30-days window or 5 half-lives will be derived from the date of the last blood collection or dosing, whichever is later, in the previous study to Day 1 of Period 1 of the current study.

    Contacts and Locations

    Locations

    SiteCityStateCountryPostal Code
    1CelerionBelfastUnited KingdomBT9 6AD

    Sponsors and Collaborators

    • Takeda

    Investigators

    • Study Director: Study Director, Takeda

    Study Documents (Full-Text)

    None provided.

    More Information

    Additional Information:

    Publications

    None provided.
    Responsible Party:
    Takeda
    ClinicalTrials.gov Identifier:
    NCT05098041
    Other Study ID Numbers:
    • TAK-935-1009
    First Posted:
    Oct 28, 2021
    Last Update Posted:
    Nov 26, 2021
    Last Verified:
    Nov 1, 2021
    Individual Participant Data (IPD) Sharing Statement:
    Yes
    Plan to Share IPD:
    Yes
    Studies a U.S. FDA-regulated Drug Product:
    Yes
    Studies a U.S. FDA-regulated Device Product:
    No
    Product Manufactured in and Exported from the U.S.:
    No
    Keywords provided by Takeda
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Nov 26, 2021